{"filing":{"accession_number":"0001193125-26-335098","cik":"0001858848","ticker":"TNYA","company_name":"Tenaya Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"tnya-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1858848/000119312526335098/tnya-20260805.htm"},"events":[{"id":24733,"run_id":22427,"accession_number":"0001193125-26-335098","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Tenaya Therapeutics issued a press release on August 5, 2026 announcing financial results for the quarter ended June 30, 2026, including condensed statements of operations and balance sheet data. The filing discloses Q2 2026 net loss of $43.4 million (versus $23.3 million in Q2 2025), R\u0026D and G\u0026A expenses, and cash position of $78.1 million. This is a standard quarterly earnings release with financial statements and operational updates, fitting the earnings_release category under Item 2.02.","company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25391,"accession_number":"0001193125-26-335098","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Tenaya Therapeutics issued a press release on August 5, 2026 announcing financial results for the quarter ended June 30, 2026, including condensed statements of operations and balance sheet data. The filing discloses Q2 2026 net loss of $43.4 million (versus $23.3 million in Q2 2025), R\u0026D and G\u0026A expenses, and cash position of $78.1 million. This is a standard quarterly earnings release with financial statements and operational updates, fitting the earnings_release category under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:17:05.478053+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25391,"accession_number":"0001193125-26-335098","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Tenaya Therapeutics issued a press release on August 5, 2026 announcing financial results for the quarter ended June 30, 2026, including condensed statements of operations and balance sheet data. The filing discloses Q2 2026 net loss of $43.4 million (versus $23.3 million in Q2 2025), R\u0026D and G\u0026A expenses, and cash position of $78.1 million. This is a standard quarterly earnings release with financial statements and operational updates, fitting the earnings_release category under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:17:05.478053+00:00","company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","filing_date":"2026-08-05"}]}